Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your own fat cells help restore skin color in vitiligo?

NCT ID NCT07763262

Disease control Sponsor: Benha University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests whether injecting a specially processed form of a patient's own fat tissue, called nanofat, can improve repigmentation in stable vitiligo when combined with standard narrowband UVB light therapy. In each of 20 adults, one vitiligo patch receives nanofat plus light therapy, while a similar patch gets light therapy alone, allowing a direct comparison. Researchers will measure the percentage and speed of repigmentation, patient satisfaction, and any side effects to see if nanofat adds real benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Autologous nanofat injection (prepared from the participant's own fat tissue) plus NB-UVB phototherapy
What this could lead to
If effective, this approach could offer a new, natural way to improve repigmentation in stable vitiligo, potentially reducing the need for more invasive treatments.
What could go wrong
This is a small, early-stage trial with only 20 participants, so results may not apply broadly. The procedure involves harvesting fat, which carries risks like infection or discomfort, and the benefit over light therapy alone is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Apr 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Male or female patients. * Patients with clinically diagnosed stable vitiligo. * Presence of comparable vitiligo sites suitable for the split-site study design. * Ability to undergo autologous nanofat harvesting and injection. * Ability and willingness to undergo NB-UVB phototherapy three times weekly for 3 months. * Ability to comply with study follow-up and assessment procedures. * Provision of written informed consent. Exclusion Criteria: * Active or progressive vitiligo. * Active infection or inflammation at the treatment sites. * Significant uncontrolled systemic disease that could interfere with treatment or assessment. * Contraindication to NB-UVB phototherapy. * Contraindication to the nanofat harvesting or injection procedure. * Pregnancy or breastfeeding, if this was an exclusion criterion in your protocol. * Previous treatment of the selected study sites that could interfere with assessment. * Inability to comply with the study protocol or follow-up. * Any condition considered by the investigator to interfere with the safety or assessment of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vitiligo vulgaris are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vitiligo vulgaris

Contacts and locations

Locations

  • Benha faculty of medicine hospital

    Banhā, Qaluybia, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.